Pancreatic Cancer Research

ResearcherMasaryk UniversityActive in the last 2 years

Zdeněk Kala

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4187-388X; OpenAlex author ID A5025686846. Sources: OpenAlex.

Their work

Papers
24 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 3 papers · 2019: 3 papers · 2020: 1 paper · 2021: 6 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 24

  1. Artificial intelligence in pancreatic cancer histopathology and diagnostics - implications for clinical decisions and biomarker discovery? Co-author DOI 10.1186/s13008-025-00158-w↗
  2. Minimal invasive surgery of pancreatic cancer at the Department of Surgery of Masaryk university hospital Brno, Czech Republic. Last author DOI 10.33699/pis.2024.103.4.122-131↗
  3. Morphine Analgesia, Cannabinoid Receptor 2, and Opioid Growth Factor Receptor Cancer Tissue Expression Improve Survival after Pancreatic Cancer Surgery. Co-author DOI 10.3390/cancers15164038↗
  4. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  5. The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma. Co-author DOI 10.3390/biomedicines9101468↗
  6. Gene expression of cytokinesis regulators PRC1, KIF14 and CIT has no prognostic role in colorectal and pancreatic cancer. Co-author DOI 10.3892/ol.2021.12859↗
  7. Current view of neoadjuvant chemotherapy in primarily resectable pancreatic adenocarcinoma. Co-author DOI 10.4149/neo_2020_200408n372↗
  8. Risk factors of pancreatic cancer and their possible uses in diagnostics. Co-author DOI 10.4149/neo_2020_200706n699↗
  9. Helicobacter pylori infection and other bacteria in pancreatic cancer and autoimmune pancreatitis. Co-author DOI 10.4251/wjgo.v13.i8.835↗
  10. Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection. Co-author DOI 10.3390/jcm9082440↗
  11. Cell-free microRNAs as Non-invasive Diagnostic and Prognostic Bio- markers in Pancreatic Cancer. Co-author DOI 10.2174/1389202921666191217095017↗
  12. Radiofrequency ablation in pancreatic cancer. Last author DOI 10.33699/pis.2019.98.11.441-449↗
  13. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection Co-author PMID 31064193↗
  14. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. Co-author DOI 10.1155/2018/5389820↗
  15. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical… Co-author DOI 10.21873/cgp.20090↗
  16. Tumor grade as significant prognostic factor in pancreatic cancer: validation of a novel TNMG staging system. Co-author DOI 10.4149/neo_2018_171012n650↗
  17. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  18. Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. Co-author DOI 10.1038/tpj.2016.55↗
  19. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. Co-author DOI 10.3892/ol.2017.6946↗
  20. MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13000-015-0272-6↗
  21. [Standardization of pancreatic cancer specimen pathological examination]. Last author PMID 24720716↗
  22. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Co-author DOI 10.1007/s00280-013-2246-2↗
  23. Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. Co-author DOI 10.1097/mpa.0b013e318279b861↗
  24. Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion. Co-author PMID 22187705↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jan Hlavsa · 13 shared papers, 2013–2025 · strength 1.28
  2. Vladimír Procházka · 6 shared papers, 2015–2025 · strength 0.79
  3. Ondřej Slabý · 7 shared papers, 2015–2021 · strength 0.71
  4. Michal Eid · 4 shared papers, 2021–2025 · strength 0.70
  5. Lumír Kunovský · 5 shared papers, 2018–2021 · strength 0.66
  6. Jan Trna · 4 shared papers, 2018–2021 · strength 0.53
  7. Igor Kišš · 5 shared papers, 2015–2020 · strength 0.45
  8. Petr Moravčík · 2 shared papers, 2024–2025 · strength 0.44
  9. Natalia Gabło · 4 shared papers, 2018–2020 · strength 0.41
  10. Martin Loveček · 4 shared papers, 2017–2023 · strength 0.40
  11. Martin Oliverius · 6 shared papers, 2013–2021 · strength 0.35
  12. Pavel Souček · 6 shared papers, 2013–2021 · strength 0.35
  13. Beatrice Mohelníková-Duchoňová · 6 shared papers, 2013–2021 · strength 0.35
  14. Petra Weselá · 1 shared paper, 2025 · strength 0.27
  15. Petr Vaňhara · 1 shared paper, 2025 · strength 0.27
  16. Jiřı́ Mayer · 2 shared papers, 2021 · strength 0.25
  17. Jiří Dolina · 2 shared papers, 2018–2021 · strength 0.21
  18. Jitka Lang · 1 shared paper, 2021 · strength 0.19
  19. Lubomír Večeřa · 1 shared paper, 2023 · strength 0.16
  20. Marián Hajdúch · 1 shared paper, 2023 · strength 0.16
  21. Markéta Hermanová · 3 shared papers, 2011–2018 · strength 0.15
  22. Radmila Lemstrová · 3 shared papers, 2017 · strength 0.15
  23. David J. Hughes · 3 shared papers, 2017 · strength 0.15
  24. Petr Karásek · 3 shared papers, 2011–2018 · strength 0.15
  25. Petr Dítě DrSc · 2 shared papers, 2011–2021 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.